Søren Weis Dahl
Direttore/Membro del Consiglio presso PILA PHARMA AB
Profilo
Søren Weis Dahl is currently the Chief Executive Officer & Director at Deck Therapeutics, Inc. and a Director at Pila Pharma AB.
He was previously the Chief Executive Officer at Prophylix AS from 2015 to 2019.
Dahl holds an MBA from Copenhagen Business School, a doctorate from the Technical University of Denmark, and a graduate degree from the same institution.
Posizioni attive di Søren Weis Dahl
| Società | Posizione | Inizio |
|---|---|---|
| PILA PHARMA AB | Direttore/Membro del Consiglio | 30/05/2023 |
Deck Therapeutics, Inc.
 Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020. | Amministratore Delegato | 01/01/2014 |
Precedenti posizioni note di Søren Weis Dahl
| Società | Posizione | Fine |
|---|---|---|
Prophylix AS
 Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Amministratore Delegato | 01/01/2019 |
Formazione di Søren Weis Dahl
| Technical University of Denmark | Graduate Degree |
| Copenhagen Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PILA PHARMA AB | Health Technology |
| Aziende private | 2 |
|---|---|
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Health Technology |
Deck Therapeutics, Inc.
Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020. | Health Technology |
- Borsa valori
- Insiders
- Søren Weis Dahl
